Filament Health operates one of the first GMP facilities in the world to also have a Health Canada Dealer’s License. This enables us to propagate psychedelic plants, conduct genetic research, perform extraction procedures, run in-house trials, and distribute IP and drug candidates. Our research program intends to include all controlled natural psychedelics including DMT, harmaline, mescaline, and more.
GMP Facility with Health Canada Dealer’s License
These certifications enable Filament Health to supply in-house trials, and distribute IP and drug candidates to drug developers, researchers, and other licensed parties.
Health Canada Dealer’s License (#6-1289) permits:
Propagation, extraction and production
Distribution and sale
Drug Development Platform
While advancing our leading drug candidates, we will continue to build out our discovery pipeline, leaning on our natural extraction expertise to access the vast potential of psychoactive plant and fungi species.
With hundreds of species to be explored, and the possibility of proving the entourage effect, we believe there is potential for many new natural psychedelic medicines to become available in the near term.
Filament Health’s drug development platform has led to the discovery and patent filings on important methods of extraction and purification. Unlike synthetic drugs which can have thousands of variations, there are few effective ways to extract and purify the compounds in plants. We believe this is important intellectual property that must be handled with great care.
Overview of Filament’s patent family
Grow botanical psychedelics
Remove target compounds from biomass
Remove undesirable elements
Different methods and forms
Patent Family at a Glance
Patent Family Deeper Dive
Our Clinical Trials
One drug platform – many trials.
Filament’s platform allows for possibly hundreds of drugs to be discovered and run through clinical trials by Filament or in partnership with other companies.
Two of Filament’s unique patent-protected drug candidates will enter two separate FDA investigator-initiated human clinical trials in 2021.